Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body
Launched by UCB PHARMA · Aug 12, 2009
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • healthy, white, male volunteers between 18 and 55 years of age (inclusive)
- • BMI between 19 and 28 kg/m² (inclusive)
- Exclusion Criteria:
- • previous participation in a clinical study with Rotigotine
- • history or current condition of epilepsy and/or seizures
- • known clinically relevant allergy or known/suspected clinically relevant drug hypersensitivity
- • history of significant skin hypersensitivity to adhesives or other transdermal products or recently unresolved contact dermatitis
- • history or present condition of an atopic or eczematous dermatitis, psoriasis, and/or an active skin disease
- • clinically relevant abnormality in physical examination, ECG, vital signs or safety laboratory examinations
- • positive HIV, hepatitis B or C test or positive alcohol or drug test
- • relevant hepatic or renal dysfunction
- • intake of medication that might interfere with the test drug within 2 weeks prior to dosing
- • thickly hair-covered abdomen resulting in difficulties in finding appropriate patch application sites
About Ucb Pharma
UCB Pharma is a global biopharmaceutical company dedicated to discovering and delivering innovative treatments for severe diseases in neurology and immunology. With a strong focus on research and development, UCB leverages cutting-edge science and technology to advance its pipeline of therapies aimed at improving the quality of life for patients. Committed to collaboration and patient-centricity, UCB engages with healthcare professionals and patient communities to ensure its clinical trials address unmet medical needs and contribute to the advancement of healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Neuss, Nrw, Germany
Patients applied
Trial Officials
UCB Clinical Trial Call center
Study Director
+1 877 822 9493 (UCB)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials